Influence of alpha-adrenergic blockade on the catecholamine response to exercise at 4,300 meters.
This investigation examined the influence of alpha-adrenergic blockade on plasma and urinary catecholamine responses to both exercise and high-altitude exposure. Sixteen nonsmoking, eumenorrheic women (age 23.2 +/- 1.4 years, 68.7 +/- 1.0 kg) were studied at sea level and during 12 days of high-altitude exposure (4,300 m). Subjects received either alpha-blockade (prazosin 3 mg/d) or a placebo in a double-blinded, randomized fashion. Resting plasma and 24-hour urine samples were collected periodically throughout the duration of the study. Further, subjects participated in submaximal exercise tests (50 minutes at 50% sea level maximum oxygen consumption [Vo2max]) at Sea level and on days 1 and 12 at altitude. Urinary norepinephrine (NE) excretion rates increased significantly over time at altitude, with blocked subjects having greater values compared to controls. Plasma NE levels increased significantly with chronic altitude exposure compared to sea level and acute hypoxia both at rest and during exercise. NE levels at rest were greater for blocked compared to control subjects during all conditions. Urinary and plasma epinephrine (EPI) levels increased dramatically, with acute altitude exposure returning to sea level values by day 12 of altitude exposure. EPI levels were greater for blocked compared to placebo both at rest and during exercise for all conditions studied. Changes in alpha-adrenergic activity over time at altitude were associated with select metabolic and physiologic adjustments. The presence of alpha-blockade significantly affected these responses during chronic altitude exposure. It was concluded that: (1) alpha-adrenergic blockade elicited a potentiated sympathoadrenal response to the stress of both exercise as well as high-altitude exposure, and (2) the sympathetics, via alpha-adrenergic stimulation, contribute to a number of key adaptations associated with acclimatization to high altitude.
Mazzeo
Robert S
RS
Department of Kinesiology and Applied Physiology, University of Colorado, Boulder 80309, USA.
Dubay
Andrea
A
Kirsch
Jennifer
J
Braun
Barry
B
Butterfield
Gail E
GE
Rock
Paul B
PB
Wolfel
Eugene E
EE
Zamudio
Stacy
S
Moore
Lorna G
LG
D000064:Acclimatization / Q000187:drug effects / Q000502:physiology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000328:Adult; D000531:Altitude; D001481:Basal Metabolism / Q000187:drug effects / Q000502:physiology; D002395:Catecholamines / Q000097:blood* / Q000652:urine; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000502:physiology; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D010656:Phenylephrine / Q000494:pharmacology; D010953:Plasma Volume / Q000187:drug effects / Q000502:physiology; D011224:Prazosin / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D010656:Phenylephrine; D011374:Progesterone; D004958:Estradiol; D011224:Prazosin